(Q43859938)

27 November 2017

title

Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial (English)

1 reference

27 November 2017

main subject

phase III clinical trial

0 references

1 reference

1

Bradley J Monk

1 reference

27 November 2017

Stanley B Kaye

2

1 reference

27 November 2017

Andrés Poveda

3

1 reference

27 November 2017

Thomas J Herzog

4

1 reference

27 November 2017

Miguel Aracil

5

1 reference

27 November 2017

Antonio Nieto

6

1 reference

27 November 2017

Nadia Badri

7

1 reference

27 November 2017

Trilok V Parekh

8

1 reference

27 November 2017

Adnan Tanović

9

1 reference

27 November 2017

Carlos M Galmarini

10

1 reference

27 November 2017

language of work or name

English

0 references

publication date

5 November 2013

1 reference

27 November 2017

1 reference

27 November 2017

volume

132

1 reference

27 November 2017

issue

1

1 reference

27 November 2017

page(s)

176-180

1 reference

27 November 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Global cancer statistics, 2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

7 January 2021

Carcinoma of the Ovary

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Progress in the management of gynecologic cancer: consensus summary statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Biomarkers for screening, diagnosis, and monitoring of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Ovarian cancer molecular pathology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Further Insight into the DNA Recognition Mechanism of Trabectedin from the Differential Affinity of Its Demethylated Analogue Ecteinascidin ET729 for the Triplet DNA Binding Site CGA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Modelling and simulation: a computational perspective in anticancer drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Tissue microarray technology for high-throughput molecular profiling of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

DNA repair: The Nijmegen breakage syndrome protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Nijmegen breakage syndrome: consequences of defective DNA double strand break repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

The MRE11 complex: starting from the ends.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

The Mre11 complex: at the crossroads of dna repair and checkpoint signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Nijmegen breakage syndrome gene (NBS1) alterations and its protein (nibrin) expression in human ovarian tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Allelic loss in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Nijmegen breakage syndrome. The International Nijmegen Breakage Syndrome Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.10.032

10.1016/J.YGYNO.2013.10.032

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference